

VRL/SEC/EXCHANGE

26.05.2025

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM</p>	<p>BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai Script Code: 526953</p>
---	--

Sub: Outcome of the Board Meeting dated 26th May 2025 under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This has reference to the meeting of Board of Directors held on 26th May 2025 inter alia considered and approved as below:

1. Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March 2025 along with Auditors' report, enclosed herewith.
2. Re-appointment of Mr. Pawan Chaudhary DIN: 00435503 as Managing Director for the period of five years w.e.f. 1st August 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company
3. Re-appointment of Mr. Peeyush Jain (DIN: 00440361) as Deputy Managing Director for the period of five years w.e.f. 1st August 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
4. Re-appointment of Mr. Ashutosh Jain (DIN: 01336895) as Executive Director for the period of five years w.e.f. 1st August 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
5. Re-appointment of Mr. Akshansh Chaudhary (DIN: 08786627) as Executive Director for the period of five years w.e.f. 26th May 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
6. Re-appointment of Mr. Navdeep Sud (DIN: 008764371) as Non Executive Independent Director for 2nd term of five years w.e.f.19th June 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
7. Appointed M/s P. Chadha & Associates, Company Secretaries as the Secretarial Auditors of the company for the period of 5 years commencing from FY 2025-2026 subject to approval of Shareholders in ensuing Annual General meeting
8. Appointed M/s C. L. Bansal & Associates, Cost Accountants as Cost Auditors of the Company for FY 2025-26.
9. Appointed M/s Mehra Goel & Co, Chartered Accountants as Internal Auditors of the Company for FY 2025-26

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.vmrindia.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany



The details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to appointments/re-appointments of directors, Internal Auditor, cost auditor and Secretarial auditors are furnished in annexure herewith.

Meeting Commenced at 04:30 pm and concluded at 10:00 pm.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmcindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany



Particulars	M/s P. Chadha & Associates, Company Secretaries as Secretarial Auditors	M/s C. L. Bansal & Associates, Cost Accountants as Cost Auditors	M/s Mehra Goel & Co, Chartered Accountants as Internal Auditors
Reason for change	Appointment	Appointment	Appointment
Date and term of appointment	Appointed on 26 th May 2025 for five financial years commencing from FY 2025-26, subject to shareholders approval.	Appointed on 26 th May 2025 for the financial year 2025-26.	Appointed on 26 th May 2025 for the financial year 2025-26.
Brief profile	M/s P. Chadha & Associates is a reputed firm of Company Secretaries in Chandigarh, offering a wide range of professional services, with a strong accent on Secretarial Audit.	M/s CL Bansal & Associates is a reputed firm of Cost Accountants in Tricity, offering a wide range of professional services in the field of Cost audit ranging from compliance, record maintenance, cost analysis etc.	Mehra Goel & Co is an Accounting firm which was setup in the year 1963. The service portfolio of Mehra Goel includes Audit, Taxation, Advisory, Management Consulting, Financial restructuring and Secretarial Services. The industry experience of Mehra Goel includes the core sectors of Steel, Telecom, Banking, energy and Automobiles. In addition, the firm has been working extensively in the textile exports, Chemicals and more recently in the BPO industry.
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable	Not Applicable	Not Applicable

VRL/SEC/EXCHANGE

26.05.2025

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM	BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001 Script Code: 526953
--	---

Sub: Submission of Audited Financial results for the quarter and year ended on 31.03.2025

Dear Sir/Madam,

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the following:

1. Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31.03.2025 along with Auditors' Report.
2. Declaration in respect of Auditors' Report with un-modified opinion for financial results as on 31st March 2025.
3. Declaration of not applicability of Large Corporates.

This is for your information and records.

Thanking you.

Yours faithfully,
for Venus Remedies Limited

Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany





J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

Independent Auditor's Report on Quarter and Year ended Standalone financial results of the VENUS REMEDIES LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To
The Board of Directors of
VENUS REMEDIES LIMITED

Opinion

1. We have audited the accompanying statement of standalone financial results of **VENUS REMEDIES LIMITED** (the "Company") for the quarter and year ended March 31, 2025 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the statement:
 - i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended in this regard and
 - ii. give a true and fair view in conformity with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the company for the quarter and year ended 31 March 2025.

Basis for Opinion

3. We conducted our audit of standalone financial results in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone Financial Results.

Emphasis of Matter

4. We draw attention to Note 3 of the accompanying financial results, which describes that the Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) Liability of USD 4.59 Million (Rs 38.68 crores), which has remained unclaimed for over 10 years and is no longer



enforceable under applicable laws. Accordingly, the outstanding principal amount of the FCCB liability of ₹28.77 crores has been transferred from Unsecured Loans to the Capital Reserve, considering its nature as a capital receipt. While the unpaid accrued interest component of ₹9.91 crores, being of revenue nature, has been recognized as an exceptional item in the Statement of Profit and Loss.

Our opinion is not modified in respect of above matter.

Management Responsibilities for Standalone Financial Results

5. This Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for preparation and presentation of the statement that gives a true and fair view of the net profit and other comprehensive income of the company and other financial information in accordance with applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control, that were operating effectively for ensuring accuracy and completeness of accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and are free from material misstatement, whether due to fraud or error.
6. In preparing the statement, the Board of Directors are responsible for assessing company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using going concern basis of accounting unless the Board of directors either intends to liquidate the company or to cease the operations, or has no realistic alternative but to do so.
7. The Board of Directors are responsible for overseeing Company's financial reporting process.

Auditors Responsibilities for the audit of Standalone Financial Results

8. Our objectives are to obtain reasonable assurance about whether the Standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act



we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Standalone financial results in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Standalone financial results, including the disclosures, and whether the Standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.
11. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during the audit.
12. We also provide those charged with governance with a statement that we have complied with relevant ethical regarding independence, and to communicate with them all relationship and other matters that reasonably be thought to bear on our independence and where applicable, related safeguards.

For J.K Jain & Associates

Chartered Accountants (FRN: 004025N)

J. K. Jain
J.K Jain

Partner

M. No.: 083140

UDIN:

Date: 26th May, 2025

Place: Panchkula

UDIN: 25083140BMSCJD4877





STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2025

(Rs. In Crores except EPS)


S. No.	PARTICULARS	QUARTER ENDED ON			YEAR ENDED ON	
		31/03/2025	31/12/2024	31/03/2024	31/03/2025	31/03/2024
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue					
	(a) Revenue from Operations	194.04	172.54	175.16	639.46	575.21
	(b) Other Income	6.77	1.74	3.91	20.78	11.32
	Total Income	200.81	174.28	179.07	660.24	586.53
2	Expenses					
	(a) Cost of Material Consumed	104.21	97.61	89.54	348.82	344.15
	(b) Purchase of stock in trade	2.13	5.50	2.67	25.04	13.07
	(c) Changes in inventories of finished goods, work-in-progress & Stock in Trade	(4.00)	2.38	12.79	0.93	(5.00)
	(d) Employee benefits expense	19.32	17.39	17.21	72.24	62.13
	(e) Depreciation & amortization expense	4.49	5.20	5.72	21.62	25.55
	(f) Selling, Manufacturing and Administrative expenses	41.32	23.34	26.52	104.15	87.81
	(g) Research & Development expenses	8.51	3.41	3.16	18.29	12.17
	Total Expense	175.98	154.83	159.60	591.09	539.88
3	Profit before taxes (1-2)	24.83	19.45	19.47	69.15	46.65
4	Exceptional Items	-	9.91	-	9.91	-
5	Profit after exceptional items (3 + 4)	24.83	29.36	19.47	79.06	46.65
	EBIDTA (3+2e)	29.32	24.65	25.19	90.77	72.21
6	Tax Expenses					
A	Current Tax	5.28	7.38	4.90	18.93	11.74
B	Deferred Tax	1.83	(2.10)	1.58	4.65	3.93
C	Tax expense related to previous year	2.93	-	0.48	2.93	0.48
7	Net Profit / (Loss) for the period (5 - 6)	14.79	24.08	12.51	52.55	30.50
8	Other Comprehensive Income					
A	(I) Items that will not be reclassified to Profit & loss	(0.34)	(0.05)	0.16	(0.48)	(0.19)
B	(I) Items that may be reclassified to Profit & loss	(0.27)	(2.06)	-	0.05	0.23
C	Total other comprehensive Income Net of Income Tax	(0.61)	(2.11)	0.16	(0.43)	0.04
9	Total comprehensive Income for the period (7+/-8)	14.18	21.97	12.68	52.12	30.54
10	Paid up equity share capital (Face Value of Equity Shares)	13.37 10	13.37 10	13.37 10	13.37 10	13.37 10
11	Other Equity	-	-	-	576.13	495.22
12	Earning per share (of Rs. 10/- each)					
	(a) Basic (₹)	11.07	18.02	9.36	39.32	22.82
	(b) Diluted (₹)	11.07	18.02	9.36	39.32	22.82




AUDITED STATEMENT OF STANDALONE CASH FLOW FOR THE PERIOD ENDED 31ST MARCH 2025

(₹ in Crore)

	PARTICULARS	For the Year	For the
		Ended	Year Ended
		31/03/2025	31/03/2024
		Audited	Audited
A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax	69.16	46.65
	Adjustment for Depreciation	21.62	25.55
	Adjustment for loss/(profit) on sale of Property plant and Equipment	1.08	(0.06)
	Rent Received	(0.41)	(0.39)
	Allowances for credit impaired trade receivables	-	0.06
	Gain on sale of Mutual Funds	(1.63)	(0.55)
	Exchange Fluctuation	(2.11)	(1.09)
	Interest Received	(4.54)	(4.16)
	Operating Profit before working capital changes	83.17	66.01
	Less: Tax Paid	(14.92)	(15.48)
	Adjustments for increase /decrease in Current Assets	(3.67)	(14.42)
	Decrease / Increase in Current Liabilities/ Provisions	27.38	(0.02)
	Decrease / Increase in Others Non-Current Assets and Other Financial Assets	(2.06)	(2.28)
	Provision for gratuity, leave encashment and Income tax	(6.80)	1.58
	Net Cash Flow from operating activities (A)	83.10	35.38
B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Rent Received	0.41	0.39
	Purchase of Property plant and equipment	(9.58)	(9.05)
	Purchase of Intangible Assets	(8.45)	(4.20)
	Sale of Property plant and equipment	0.20	0.48
	Investment in Mutual Funds	(64.95)	0.72
	Gain on sale of Mutual Funds	1.63	0.55
	Interest Received	4.54	4.16
	Net Cash Flow from Investing Activities (B)	(76.20)	(6.94)
C)	CASH FLOW FROM FINANCING ACTIVITIES		
	Net Cash from Financing Activities (C)	-	-
	Net Increase in Cash & Cash Equivalents (A+B+C)	6.90	28.44
	Opening Cash & Cash Equivalents	48.51	20.07
	Closing Cash & Cash Equivalents	55.41	48.51



Audited Statement of Standalone Assets and Liabilities		
Particulars	(₹ In Crore)	
	As at 31/03/2025 (Audited)	As at 31/03/2024 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment	110.93	119.03
(b) Capital Work in Progress	26.39	21.08
(c) Intangible Assets	103.21	83.73
(d) Financial Assets		
(i) Investments	0.16	0.16
(ii) Other Financial Assets	34.30	33.82
(e) Other Non-Current Assets	2.48	22.44
Total Non Current Assets	277.47	280.26
Current Assets		
(a) Inventories	100.49	117.81
(b) Financial Assets		
(i) Investment	84.09	19.09
(ii) Trade Receivables	99.26	89.54
(iii) Cash and Cash Equivalents	55.41	48.51
(iv) Others Bank Balances	22.58	19.14
(v) Other Financial Assets	0.38	0.21
(c) Current Tax Assets	10.86	29.98
(d) Other Current Assets	62.68	36.72
Total Current Assets	435.75	361.00
Total Assets	713.22	641.26
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	13.37	13.37
(b) Other Equity	576.13	495.22
Total equity	589.50	508.59
Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings		
(a) Unsecured	-	38.68
(b) Provisions	2.90	10.26
(c) Deferred Tax Liabilities (Net)	15.58	10.92
Total Non-Current Liabilities	18.48	59.86
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables		
(a) Total outstanding dues of micro enterprises and small enterprises	6.05	2.74
(b) Total outstanding dues of creditors other than micro and small enterprises	62.56	49.00
(ii) Other Financial Liabilities	25.35	18.82
(b) Other Current Liabilities	5.20	1.20
(c) Provisions	6.08	1.05
Total Current Liabilities	105.24	72.81
Total Equity and Liabilities	713.22	641.26






Notes to the standalone financial results: -

1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 26th May 2025. The statutory auditors of the company have carried out limited review of the above Standalone Financial Result for the quarter and year ended 31st March 2025, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Standalone Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) liability of ₹38.68 crores, which has remained unclaimed for over 10 years and is no longer legally enforceable under applicable laws. Accordingly, the outstanding principal amount of the FCCB liability of ₹28.77 crores has been transferred to the Capital Reserve, considering its nature as a capital receipt, while the accrued interest component of ₹9.91 crores, being revenue in nature, has been recognized as an exceptional item in the Statement of Profit and Loss.
4. The figures for last quarter are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to the third quarter of the current financial year.
5. There is no material adjustments made to the results of the 4th quarter pertain to earlier periods.
6. The company has a wholly owned subsidiary named Venus Pharma GmbH in Germany and step-down subsidiary of Venus Pharma GmbH named as Venus Pharma Kft in Hungary.
7. Previous year / period figures have been regrouped/ reclassified wherever necessary.

For and on behalf of Board of Directors
for VENUS REMEDIES LIMITED


Pawan Chaudhary
(Managing Director)
Din: 00435503

Date: 26-05-2025





J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

Independent Auditor's Report on Quarter and Year ended consolidated financial results of the VENUS REMEDIES LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

**To
The Board of Directors of
VENUS REMEDIES LIMITED**

Opinion

1. We have audited the accompanying statement of Consolidated Financial Results of VENUS REMEDIES LIMITED ("the Holding Company") and its subsidiary (collectively referred to as 'the Group'), for the Quarter and Year ended 31st March 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of other auditor on separate audited financial results of the Subsidiary referred to in Other Matter section below, the Statement
 - i. includes the financial results of the following Subsidiary:
 - a. Venus Pharma GmbH
 - b. Venus.Pharma Kft (Subsidiary of Venus Pharma GmbH)
 - ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended in this regard, and
 - iii. give a true and fair view in conformity with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter and year ended 31st March 2025.

Basis for Opinion

3. We conducted our audit of the consolidated financial results in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of



Ethics. We believe that the audit evidence obtained by us and that obtained by other auditor in terms of their report referred to in paragraph 14 of other matter section below, is sufficient and appropriate to provide a basis for our audit opinion on the Consolidated Financial Results.

Emphasis of Matter

4. We draw attention to Note 3 of the accompanying financial results, which describes that the Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) Liability of USD 4.59 Million (Rs 38.68 crores), which has remained unclaimed for over 10 years and is no longer legally enforceable under applicable laws. Accordingly, the outstanding principal amount of the FCCB liability of ₹28.77 crores has been transferred from Unsecured Loans to the Capital Reserve, considering its nature as a capital receipt. While the unpaid accrued interest component of ₹9.91 crores, being of revenue nature, has been recognized as an exceptional item in the Statement of Profit and Loss.

Our opinion is not modified in respect of above matter.

Management Responsibilities for Consolidated Financial Results

5. This Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of consolidated financial results. The Board of Directors of the Holding Company are responsible for preparation and presentation of the statement that gives a true and fair view of the Consolidated Net Profit other comprehensive income of the Group and other financial information in accordance with applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control, that were operating effectively for ensuring the accuracy and completeness of accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
6. In preparing the statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using going concern basis of accounting unless the respective Board of directors either intends to liquidate their respective entities or to cease the operations, or has no realistic alternative but to do so.
7. The respective Board of Directors/ management of the companies included in the Group, are responsible for overseeing the financial reporting process of the companies included in the Group.

Auditors Responsibilities for the audit of Consolidated Financial Results



8. Our objectives are to obtain reasonable assurance about whether the statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated financial Results.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial results in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the statements, including the disclosures, and whether the statements represent the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



10. Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.
11. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during the audit.
12. We also provide those charged with governance with a statement that we have complied with relevant ethical regarding independence, and to communicate with them all relationship and other matters that reasonably be thought to bear on our independence and where applicable, related safeguards.
13. We also performed procedures in accordance with SEBI Circular CIR/CFD/CMD1/44/2019 dated 29th March 2019, issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matter

14. We have audited the financial results of the subsidiaries included in the statement. These include:
Venus Pharma GmbH, whose financial results / financial information reflect total assets of Rs. 35.84 crores as at 31st March, 2025, total revenues of Rs. 38.70 crores, total net loss after tax of Rs. 7.10 crores, and net cash inflows amounting to Rs. 2.27 crores for the year ended on that date.

Venus Pharma Kft, a subsidiary of Venus Pharma GmbH, whose financial results / financial information reflect total assets of Rs. 0.07 crores, total revenues of Rs. 0.00 crores, total net profit/loss after tax of Rs. 0.19 crores, and net cash flows of Rs. 0.00 crores for the year ended on that date.

These financial results have been audited by us and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on our audit report and the procedures performed by us as stated in paragraph 9 above.

Further, subsidiary is located outside India, whose financial results have been prepared in accordance with accounting principles generally accepted in India, and which have been audited by us under standard of auditing applicable in India. Our opinion, in so far as it relates to the balances and affairs of the subsidiary, is based on our audit report.

For J.k Jain & Associates
Chartered Accountants (FRN: 004025N)

J. K. Jain

J.K Jain
Partner
M. No.: 083140
UDIN:



Date: 26th May, 2025
Place: Panchkula
UDIN: 25083140BMSCJE4304

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025


(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			YEAR ENDED ON	
		31/03/2025	31/12/2024	31/03/2024	31/03/2025	31/03/2024
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue					
	(a) Revenue from Operations	194.97	176.86	195.16	647.89	601.45
	(b) Other Income	6.76	2.03	3.92	20.96	11.58
	Total Income	201.73	178.89	199.08	668.85	613.03
2	Expenses					
	(a) Cost of Material Consumed	104.21	97.52	84.17	348.77	344.28
	(b) Purchase of stock in trade	2.13	5.50	2.67	25.04	13.07
	(c) Changes in Inventories of finished goods, work-in-progress & Stock in Trade	(3.28)	7.18	33.20	4.81	(2.66)
	(d) Employee benefits expense	21.16	19.55	19.71	80.49	71.50
	(e) Finance Cost	0.01	0.01	0.02	0.07	0.09
	(f) Depreciation & amortization expense	4.71	5.41	5.91	22.51	26.44
	(g) Selling, Manufacturing and Administrative expenses	37.06	24.72	31.16	107.16	99.82
	(h) Research & Development expenses	4.69	4.03	4.78	18.08	15.84
	Total Expense	170.89	163.92	181.61	606.93	568.39
3	Profit before taxes (1-2)	31.04	14.97	17.48	61.92	44.64
4	Exceptional Items	-	9.91	-	9.91	-
5	Profit after exceptional items (3 + 4)	31.04	24.88	17.48	71.83	44.64
	EBIDTA (3+2e+2f)	35.77	20.39	23.39	84.49	71.18
6	Tax Expense					
A	Current Tax	5.28	7.38	4.90	18.93	11.74
B	Deferred Tax	1.83	(2.10)	1.58	4.65	3.93
C	Tax expense related to previous year	2.93	-	0.48	2.93	0.48
7	Net Profit / (Loss) for the period (5 - 6)	21.00	19.60	10.51	45.32	28.49
8	Other Comprehensive Income					
A	(i) Items that will not be classified to profit & loss	(0.34)	(0.05)	0.16	(0.48)	(0.19)
B	(l) Foreign Currency Translation Reserve	(0.20)	0.36	0.17	(0.25)	(1.32)
C	(l) Items that will be classified to profit & loss	(0.27)	(2.06)	-	0.05	0.23
	Total other comprehensive Income Net of Income Tax	(0.81)	(1.75)	0.33	(0.68)	(1.28)
9	Total comprehensive Income for the period (7+/-8)	20.19	17.85	10.84	44.64	27.21
10	Paid up equity share capital (Face Value of Equity Shares)	13.37	13.37	13.37	13.37	13.37
		10	10	10	10	10
11	Other Equity	-	-	-	547.58	474.18
12	Earning per share (of Rs. 10/- each)					
	(a) Basic	15.71	14.66	7.86	33.90	21.31
	(b) Diluted	15.71	14.66	7.86	33.90	21.31



AUDITED STATEMENT OF CONSOLIDATED CASH FLOW FOR THE PERIOD ENDED 31ST MARCH 2025

		(₹ in Crore)	
PARTICULARS		For the Year ended 31/03/2025	For the Year ended 31/03/2024
		Audited	Audited
A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax	61.87	44.64
	Adjustment for Depreciation	22.51	26.44
	Adjustment for loss/(profit) on sale of Property plant and Equipment	1.08	(0.06)
	Interest Expense	0.07	0.09
	Rent Received	(0.41)	(0.39)
	Allowances for credit impaired trade receivables	-	0.06
	Gain on sale of Mutual Fund	(1.63)	(0.55)
	Exchange Fluctuation	(2.11)	(1.20)
	Interest Received	(4.54)	(4.16)
	Operating Profit before working capital changes	76.84	64.88
	Less Tax Paid	(14.92)	(15.48)
	Adjustments for increase /decrease in Current Assets	12.97	(43.36)
	Decrease / Increase in Current Liabilities/ Provisions	20.42	31.95
	Decrease / Increase in Others Non-Current Assets and Other Financial Assets	(2.06)	(2.28)
	Provision for gratuity,leave encashment and Income Tax	(6.80)	1.58
	Net Cash Flow from operating activities (A)	88.45	37.29
B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Rent Received	0.41	0.39
	Purchase of Property plant and equipment	(9.63)	(9.32)
	Purchase of Intangible Assets	(8.45)	(4.20)
	Sale of Property plant and equipment	0.20	0.48
	Investment in Mutual funds	(64.95)	0.72
	Gain on sale of Mutual Fund	1.63	0.55
	Interest Received	4.54	4.17
	Net Cash Flow from Investing Activities (B)	(76.25)	(7.21)
C)	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from term Loans (Net)	(0.95)	(0.99)
	Interest Expense	(0.07)	(0.09)
	Net Cash from Financing Activities (C)	(1.02)	(1.08)
	Net Increase in Cash & Cash Equivalents (A+B+C)	9.18	28.99
	Unrealised Loss/(gain) on foreign currency cash and cash equivalents	(0.62)	(1.25)
	Opening Cash & Cash Equivalents	48.96	21.21
	Closing Cash & Cash Equivalents	57.52	48.96



Audited Statement of Consolidated Assets and Liabilities

(₹ In Crore)

Particulars	As at 31/03/2025 (Audited)	As at 31/03/2024 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment	124.70	133.32
(b) Capital work in progress	26.39	21.08
(c) Intangible Assets	104.72	85.21
(d) Financial Assets		
(i) Investments	0.02	0.02
(ii) Other Financial Assets	5.70	5.23
(e) Other Non-Current Assets	2.47	22.44
Total Non Current Assets	264.00	267.30
Current Assets		
(a) Inventories	100.49	121.69
(b) Financial Assets		
(i) Investments	84.09	19.09
(ii) Trade Receivables	112.22	80.50
(iii) Cash and Cash Equivalents	57.52	48.96
(iv) Others Bank Balances	22.58	19.14
(v) Other Financial Assets	0.86	0.74
(c) Current Tax Assets	10.86	29.98
(d) Other Current Assets	63.10	39.43
Total Current Assets	451.72	359.53
Total Assets	715.72	626.83
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	13.37	13.37
(b) Other Equity	547.58	474.18
Total equity	560.95	487.55
Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings		
(a) Unsecured	0.00	38.68
(b) Provisions	2.90	10.28
(c) Deferred Tax Liabilities (net)	15.56	10.92
Total Non-Current Liabilities	18.48	59.86
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1.69	2.65
(ii) Trade payables		
(A) Total outstanding dues of micro enterprises and small enterprises	6.05	2.74
(B) Total outstanding dues of creditors other than micro and small enterprises	85.81	50.44
(iii) Other Financial Liabilities	31.38	20.96
(b) Other Current Liabilities	5.27	1.58
(c) Provisions	6.08	1.05
Total Current Liabilities	138.29	79.42
Total Equity and Liabilities	715.72	626.83






Notes to the consolidated financial results: -

1. The above Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 26th May 2025. The statutory auditors of the holding company have carried out limited review of the above Consolidated Financial Result for the quarter and year ended 31st March 2025, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Consolidated Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) liability of ₹38.68 crores, which has remained unclaimed for over 10 years and is no longer legally enforceable under applicable laws. Accordingly, the outstanding principal amount of the FCCB liability of ₹28.77 crores has been transferred to the Capital Reserve, considering its nature as a capital receipt, while the accrued interest component of ₹9.91 crores, being revenue in nature, has been recognized as an exceptional item in the Statement of Profit and Loss.
4. The figures for last quarter are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to the third quarter of the current financial year.
5. There is no material adjustments made to the results of the 4th quarter pertain to earlier periods.
6. The parent company has a wholly owned subsidiary named Venus Pharma GmbH in Germany. Venus Pharma Kft is a step-down subsidiary of the parent company through Venus Pharma GmbH. The consolidated financial results include the results of both Venus Pharma GmbH and its step-down subsidiary Venus Pharma Kft.
7. Previous year / period figures have been regrouped/ reclassified wherever necessary.
8. The group has only one reportable segment namely "Pharmaceuticals"

**For and on behalf of Board of Directors
for VENUS REMEDIES LIMITED**


Pawan Chaudhary
(Managing Director)

Din: 00435503

Date: 26.05.2025



VRL/SEC/EXCHANGE

26.05.2025

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM</p>	<p>BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai Script Code: 526953</p>
--	---

Sub: Intimation of Re-appointment of Directors pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 (Listing Regulations).

Dear Sir/ Madam,

Please be informed that based on the recommendations of Nomination & Remuneration Committee, the Board of Directors at its meeting held on 26th May, 2025 has considered and approved as below:

1. Re-appointment of Mr. Pawan Chaudhary DIN: 00435503 as Managing Director for the period of five years w.e.f. 1st August 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
2. Re-appointment of Mr. Peeyush Jain (DIN: 00440361) as Deputy Managing Director for the period of five years w.e.f. 1st August 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
3. Re-appointment of Mr. Ashutosh Jain (DIN: 01336895) as Executive Director for the period of five years w.e.f. 1st August 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
4. Re-appointment of Mr. Akshansh Chaudhary (DIN: 08786627) as Executive Director for the period of five years w.e.f. 26th May 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.
5. Re-appointment of Mr. Navdeep Sud (DIN: 008764371) as Non Executive Independent Director for 2nd term of five years w.e.f. 19th June 2025 subject to the approval of shareholders in ensuing Annual General Meeting of the Company.

It may be further noted that as per BSE Circular No. LIST/COMP/14/2018-19 dated 20th June, 2018 and NSE Circular No. NSE/CML/2018/24 dated 20th June, 2018, and based on the information available, Mr. Akshansh Chaudhary, Mr. Pawan Chaudhary, Mr. Peeyush Jain, Mr. Ashutosh Jain and Mr. Navdeep Sud have not been debarred from holding the office of a Director by virtue of any SEBI order or any such other authority.

Other relevant details pertaining to above mentioned re-appointments are given in annexure-1 as enclosed herewith.

Thanking you.

Yours faithfully,

for VENUS REMEDIES LIMITED

Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany



Anexure

Names					
Particulars	Mr. Akshansh Chaudhary	Mr. Pawan Chaudhary	Mr. Peeyush Jain	Mr. Ashutosh Jain	Mr. Navdeep Sud
Reason for Change	Re-appointment for further period of 5 Years	Re-appointment for further period of 5 Years	Re-appointment for further period of 5 Years	Re-appointment for further period of 5 Years	Re-appointment for further period of 5 Years
Date & Term of appointment	The reappointment will be effective from 26th May 2025 for a period of five years, subject to the approval of shareholders in ensuing annual general meeting.	The reappointment will be effective from 1st August 2025 for a period of five years, subject to the approval of shareholders in ensuing annual general meeting.	The reappointment will be effective from 1st August 2025 for a period of five years, subject to the approval of shareholders in ensuing annual general meeting.	The reappointment will be effective from 1st August 2025 for a period of five years, subject to the approval of shareholders in ensuing annual general meeting.	The reappointment will be effective from 19th June 2025 for a period of five years, subject to the approval of shareholders in ensuing annual general meeting.
Brief Profile and Date of Birth(DOB)	Mr. Akshansh Chaudhary is an engineering graduate from BITS Pilani, Dubai and has done Masters in Design & Technology from Parsons School of Design, New York. He has more than 05 years of experience in IT industry. DOB: 25.03.1993	Mr. Pawan Chaudhary is a first generation entrepreneur who started the Company in 1989. A Chartered Accountant with a law degree, having a rich experience of more than three decades, his vision & value system guided the organisation towards profitable sustainability. DOB:05.05.1964	Mr. Jain has more than 25 years of experience in pharmaceutical marketing. He heads the Company's Indian marketing operations. Mr. Jain conceived and executed the brand building, marketing and promotions strategy for pan India marketing operations. DOB:01.08.1971	Mr. Ashutosh Jain is a Law graduate and is associated with the Company since 2003. Mr. Jain heads the Legal & Corporate Regulatory Affairs and Administration dept. of the company. DOB:07.05.1977	A Law Graduation from Punjab University, Chandigarh, Mr. Navdeep Sud served Punjab Govt. as Assistant District Attorney after that Joined the Central Labour Service under Ministry of Labour & Empowerment, Govt. of India. He looked after Labour Laws enforcement in big establishments like Railway, Panipat Refinery, ACC, NHPC, Banks, CPWD, FCI, HDFC, Airlines, IOC, CSIR etc. in 5 States. Mr. Sud retired as Dy. Director General in the rank of Joint Secretary to Govt. of India. Presently Mr. Sud is practicing Advocate in Punjab & Haryana High Court. DOB:02.02.1959
Disclosure of relationship between the directors	He is related to Mr. Pawan Chaudhary, Mrs. Manu Chaudhary, Mr. Peeyush Jain and Mr. Ashutosh Jain	He is related to Mrs. Manu Chaudhary, Mr. Peeyush Jain, Mr. Ashutosh Jain and Mr. Akshansh Chaudhary	He is related to Mr. Pawan Chaudhary, Mrs. Manu Chaudhary, Mr. Ashutosh Jain and Mr. Akshansh Chaudhary	He is related to Mr. Pawan Chaudhary, Mrs. Manu Chaudhary, Mr. Peeyush Jain and Mr. Akshansh Chaudhary	He is not related to any Director of the Company.
No. of shares held in the Company	1	17,13,946	50	NIL	NIL

VRL/SEC/EXCHANGE

26.05.2025

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai Script Code: 526953
---	--

Sub.: Undertaking for not falling under the criteria of Large Corporate.

Dear Sir/ Madam,

We hereby, undertake that Venus Remedies Limited does not fall under the criteria of Large Corporate as on 31st March 2025, as per the SEBI circular no. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

The disclosure as per format Annex - XII-A of SEBI Operational Circular dated August 10, 2021, disclosures are as below as on 31st March 2025:

Sr. No.	Particular	Details
1	Name of the company	Venus Remedies Limited
2	CIN	L24232CH1989PLC009705
3	Outstanding borrowing of company as on 31st March 2025 (in Rs. crore)	Nil
4	Highest credit rating during the previous FY along with name of the CRA	Not Applicable
5	Name of stock exchange* in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not Applicable

We confirm that we are **NOT** a Large Corporate as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021.


Yours faithfully,
for VENUS REMEDIES LIMITED

VENUS REMEDIES LIMITED



Neha Arora

(Company Secretary)



Rawan Chaudhary
(CFO)

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany



VRL/SEC/EXCHANGE

26.05.2025

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM</p>	<p>BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001 Script Code: 526953</p>
--	--

Sub: Declaration pursuant to Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

This is with reference to regulation 33(3)(d) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. We hereby declare that the statutory auditors of the Company have issued the Audit Report dated May 26, 2025 with unmodified opinion on the Annual Audited IND AS Financial statements (Standalone & Consolidated) of the Company for the financial year ended March 31, 2025.

The Standalone & Consolidated Financial statements have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on May 26, 2025

Kindly take the above on records and oblige.

Thanking you.

Yours faithfully,
for Venus Remedies Limited

Neha
Company Secretary

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany

